Mereo BioPharma (MREO) Total Current Liabilities (2017 - 2026)

Mereo BioPharma (MREO) has 10 years of Total Current Liabilities data on file, last reported at $6.2 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $6.2 million, down 17.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.2 million (down 17.61% YoY), and the FY2025 annual result was $4.3 million, down 68.93% from the prior year.
• Total Current Liabilities grew to $6.2 million in Q1 2026 per MREO's latest filing, from $4.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $28.9 million in Q4 2022 and troughed at $4.3 million in Q4 2025.
• A 5-year average of $11.3 million and a median of $9.5 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 71.21% in 2022, then tumbled 68.93% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $28.9 million in 2022, then slumped by 67.23% to $9.5 million in 2023, then soared by 45.98% to $13.8 million in 2024, then tumbled by 68.93% to $4.3 million in 2025, then surged by 43.58% to $6.2 million in 2026.
• Business Quant data shows MREO's Total Current Liabilities at $6.2 million in Q1 2026, $4.3 million in Q4 2025, and $6.0 million in Q3 2025.